Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Non-atopic Asthma
NCT01113437Phase 3Unknown
- Sponsor
- King's College London
- Start
- Apr 2010
- Primary completion
- Aug 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Nonatopic Asthma (NAA) comparing Omalizumab with Placebo (2 arms). Primary endpoints: Pre-bronchodilator FEV1 at 20 weeks and Disease exacerbation. Status: unknown.
02
Drugs
omalizumab
03
Conditions
Nonatopic Asthma (NAA)
Beyond the preview
Go deeper on NCT01113437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01113437.